Inhibition of PI3K/mTOR Leads to Adaptive Resistance in Matrix-Attached Cancer Cells

被引:318
|
作者
Muranen, Taru [1 ]
Selfors, Laura M. [1 ]
Worster, Devin T. [1 ]
Iwanicki, Marcin P. [1 ]
Song, Loling [1 ]
Morales, Fabiana C. [2 ]
Gao, Sizhen [1 ]
Mills, Gordon B. [2 ]
Brugge, Joan S. [1 ]
机构
[1] Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA
基金
芬兰科学院;
关键词
CAP-INDEPENDENT TRANSLATION; SIGNALING PATHWAYS; TUMOR-SUPPRESSOR; INSULIN-RECEPTOR; AKT ACTIVATION; UP-REGULATION; PI3K PATHWAY; BREAST; INITIATION; APOPTOSIS;
D O I
10.1016/j.ccr.2011.12.024
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The PI3K/mTOR-pathway is the most commonly dysregulated pathway in epithelial cancers and represents an important target for cancer therapeutics. Here, we show that dual inhibition of PI3K/mTOR in ovarian cancer-spheroids leads to death of inner matrix-deprived cells, whereas matrix-attached cells are resistant. This matrix-associated resistance is mediated by drug-induced upregulation of cellular survival programs that involve both FOXO-regulated transcription and cap-independent translation. Inhibition of any one of several upregulated proteins, including BcI-2, EGFR, or IGF1R, abrogates resistance to PI3K/mTOR inhibition. These results demonstrate that acute adaptive responses to PI3K/mTOR inhibition in matrix-attached cells resemble well-conserved stress responses to nutrient and growth factor deprivation. Bypass of this resistance mechanism through rational design of drug combinations could significantly enhance PI3K-targeted drug efficacy.
引用
收藏
页码:227 / 239
页数:13
相关论文
共 50 条
  • [41] Inhibition of PI3K/AKT/mTOR pathway for the treatment of endometriosis
    Barra, Fabio
    Desideri, Lorenzo Ferro
    Ferrero, Simone
    BRITISH JOURNAL OF PHARMACOLOGY, 2018, 175 (17) : 3626 - 3627
  • [42] Dual inhibition of PI3K and mTOR inhibits autocrine and paracrine proliferative loops in PI3K/Akt/mTOR-addicted lymphomas
    Bhatt, Aadra P.
    Bhende, Prasanna M.
    Sin, Sang-Hoon
    Roy, Debasmita
    Dittmer, Dirk P.
    Damania, Blossom
    BLOOD, 2010, 115 (22) : 4455 - 4463
  • [43] Inhibition of the PI3K/AKT/mTOR Pathway in Solid Tumors
    LoRusso, Patricia Mucci
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (31) : 3803 - +
  • [44] In vitro effects of PI3K/mTOR inhibition in canine hemangiosarcoma
    Pyuen, Alex A.
    Meuten, Travis
    Rose, Barbara J.
    Thamm, Douglas H.
    PLOS ONE, 2018, 13 (07):
  • [45] Inhibition of PI3K/Akt/mTOR Signaling by Natural Products
    Huang, Shile
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2013, 13 (07) : 967 - 970
  • [46] MAPkinase and PI3K/mTOR pathways inhibition in conjunctival melanoma
    Ei-Zaoui, Ikram El Zaoui
    Nicolas, Michael
    Gobert, Rosanna Pescini
    Rimoldi, Donata
    Leyraz, Serge
    Rivolta, Carlo
    Moulin, Alexandre
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2017, 58 (08)
  • [47] Blockage of Stat3 enhances the sensitivity of NSCLC cells to PI3K/mTOR inhibition
    Jin, Hyeon-Ok
    Lee, Yun-Han
    Park, Jin-Ah
    Kim, Jin-Hee
    Hong, Sung-Eun
    Kim, Hyun-Ah
    Kim, Eun-Kyu
    Noh, Woo Chul
    Kim, Byung-Hak
    Ye, Sang-Kyu
    Chang, Yoon Hwan
    Hong, Seok-Il
    Hong, Young-Joon
    Park, In-Chul
    Lee, Jin Kyung
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2014, 444 (04) : 502 - 508
  • [48] Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer
    Le, Xiuning
    Antony, Rajee
    Razavi, Pedram
    Treacy, Daniel J.
    Luo, Flora
    Ghandi, Mahmoud
    Castel, Pau
    Scaltriti, Maurizio
    Baselga, Jose
    Garraway, Levi A.
    CANCER DISCOVERY, 2016, 6 (10) : 1134 - 1147
  • [49] Targeting PI3K/Akt/mTOR signaling in cancer
    Porta, Camillo
    Paglino, Chiara
    Mosca, Alessandra
    FRONTIERS IN ONCOLOGY, 2014, 4
  • [50] Dual targeting of PI3K and mTOR results in synergistic growth inhibition in NSCLC cells
    Chao, Herta H.
    Zito, Christopher
    Jilaveanu, Lucia
    Anagnostou, Valsamo
    Rimm, David
    Bepler, Gerold
    Camp, Robert
    Kluger, Harriet M.
    CANCER RESEARCH, 2010, 70